ITZHAK MENDEL, PHD

Dr. Itzhak Mendel previously served as VP Immunology at Bioimmunate Technologies Ltd. Prior to that, he was Director of Immunology at VBL Therapeutics (Nasdaq: VBLT) for many years, driving the research in the MOSPD2 program that led to development of IW-601. He brings 20 years of industry experience in drug development, from discovery to clinical trials, in the field of Inflammation, cancer and immuno-oncology. 

Dr. Mendel has scientific expertise in immunology and cancer biology and has vast experience in basic and translational research in pre-clinical and clinical settings, including development of drug candidates and investigating mechanisms of action, PK/PD, biomarkers and pharmacology. 

He received his Doctor of Philosophy degree from the Weizmann Institute of Science in Rehovot, Israel and completed his post-doctroral fellowship at the National Institutes of Health (NIH).